[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,931,708
  • Shares Outstanding, K 62,377
  • Annual Sales, $ 814,760 K
  • Annual Income, $ -258,000 K
  • EBIT $ -15 M
  • EBITDA $ 5 M
  • 60-Month Beta 0.39
  • Price/Sales 19.13
  • Price/Cash Flow N/A
  • Price/Book 27.29

Options Overview Details

View History
  • Implied Volatility 50.60% (+0.89%)
  • Historical Volatility 26.82%
  • IV Percentile 67%
  • IV Rank 54.00%
  • IV High 65.95% on 01/07/26
  • IV Low 32.57% on 05/12/26
  • Expected Move (DTE 11) 6.21 (2.43%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 332
  • Volume Avg (30-Day) 218
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 11,863
  • Open Int (30-Day) 12,166
  • Expected Range 249.42 to 261.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.29
  • Number of Estimates 7
  • High Estimate $4.33
  • Low Estimate $0.60
  • Prior Year $-0.93
  • Growth Rate Est. (year over year) +238.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
239.56 +6.70%
on 08/04/26
268.77 -4.89%
on 07/15/26
-14.83 (-5.48%)
since 07/10/26
3-Month
203.80 +25.43%
on 06/08/26
282.15 -9.40%
on 07/09/26
+16.96 (+7.11%)
since 05/08/26
52-Week
186.05 +37.39%
on 10/20/25
282.15 -9.40%
on 07/09/26
+64.13 (+33.49%)
since 08/08/25

Most Recent Stories

More News
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday,...

ASND : 255.62 (+0.08%)
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

TransCon ® CNP and TransCon hGH combination therapy Week 78 data from the Phase 2 COACH Trial showed durable, unprecedented increase in healthy, proportional growth TransCon CNP monotherapy Week...

ASND : 255.62 (+0.08%)
Ascendis Pharma's First Earnings as an Ordinary Share Won't Clarify What Changed

Barchart Research What to Expect from ASND Earnings ASND Generated August 5, 2026 Current Price $244.20 EPS Estimate $$1.29 Consensus Rating Strong Buy Average Move 4.70% Ascendis Pharma's First Earnings...

ASND : 255.62 (+0.08%)
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104 Greater improvements observed in children...

ASND : 255.62 (+0.08%)
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000 ® Index, the large-cap Russell...

ASND : 255.62 (+0.08%)
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with...

ASND : 255.62 (+0.08%)
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Multi-organ system and quality-of-life benefits sustained through three and a half years  86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year...

ASND : 255.62 (+0.08%)
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years...

ASND : 255.62 (+0.08%)
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia,...

ASND : 255.62 (+0.08%)
Ascendis Pharma A/S Q1 Earnings Call Highlights

Ascendis Pharma A/S (NASDAQ:ASND) reported first-quarter 2026 results highlighted by the U.S. FDA approval of its third TransCon product, YUVIWEL, and continued growth across its rare endocrine portfolio....

ASND : 255.62 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 264.77
2nd Resistance Point 261.10
1st Resistance Point 258.36
Last Price 255.62
1st Support Level 251.94
2nd Support Level 248.26
3rd Support Level 245.52

See More

52-Week High 282.15
Last Price 255.62
Fibonacci 61.8% 245.44
Fibonacci 50% 234.10
Fibonacci 38.2% 222.76
52-Week Low 186.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.